Page 117 - OR-1-2

doi: 10.3390/cancers15174352. doi: 10.1038/s41591-020-0805-8
13. Zanella ER, Grassi E, Trusolino L. Towards precision 25. Ribas A, Lawrence D, Atkinson V, et al. Combined BRAF
oncology with patient-derived xenografts. Nat Rev Clin and MEK inhibition with PD-1 blockade immunotherapy in
Oncol. 2022;19:719-732. BRAF-mutant melanoma. Nat Med. 2019;25(6):936-940.
doi: 10.1038/s41571-022-00682-6 doi: 10.1038/s41591-019-0476-5
14. Ben-David U, Ha G, Tseng YY, et al. Patient-derived 26. Han K, Pierce SE, Li A, et al. CRISPR screens in cancer
xenografts undergo mouse-specific tumor evolution. Nat spheroids identify 3D growth-specific vulnerabilities. Nature.
Genet. 2017;49:1567-1575. 2020;580:136-141.
doi: 10.1038/ng.3967 doi: 10.1038/s41586-020-2099-x
15. Xu H, Jiao D, Liu A, Wu K. Tumor organoids: Applications 27. Jain T, Sharma P, Are AC, Vickers SM, Dudeja V. New insights
in cancer modeling and potentials in precision medicine. into the cancer-microbiome-immune axis: Decrypting a
J Hematol Oncol. 2022;15(1):58. decade of discoveries. Front Immunol. 2021;12:622064.
doi: 10.1186/s13045-022-01278-4 doi: 10.3389/fimmu.2021.622064
16. Xu R, Zhou X, Wang S, Trinkle C. Tumor organoid models 28. Ji DB, Wu AW. Organoid in colorectal cancer: Progress and
in precision medicine and investigating cancer-stromal challenges. Chin Med J (Engl). 2020;133:1971.
interactions. Pharmacol Ther. 2020;218:107668. doi: 10.1097/CM9.0000000000000882
doi: 10.1016/j.pharmthera.2020.107668 29. Matano M, Date S, Shimokawa M, et al. Modeling colorectal
17. Xu H, Lyu X, Yi M, Zhao W, Song Y, Wu K. Organoid cancer using CRISPR-Cas9 - mediated engineering of human
technology and applications in cancer research. J Hematol intestinal organoids. Nat Med. 2015;21(3):256-262.
Oncol. 2018;11:116. doi: 10.1038/nm.3802
doi: 10.1186/s13045-018-0662-9 30. Ooft SN, Weeber F, Dijkstra KK, et al. Patient-derived
18. Ma X, Wang Q, Li G, Li H, Xu S, Pang D. Cancer organoids: organoids can predict response to chemotherapy in metastatic
A platform in basic and translational research. Genes Dis. colorectal cancer patients. Sci Transl Med. 2019;11:eaay2574.
2023;11:614. doi: 10.1126/scitranslmed.aay2574
doi: 10.1016/j.gendis.2023.02.052 31. Luo X, Fong ELS, Zhu C, et al. Hydrogel-based colorectal
19. Yan HHN, Chan AS, Lai FPL, Leung SY. Organoid cultures cancer organoid co-culture models. Acta Biomater.
for cancer modeling. Cell Stem Cell. 2023;30:917-937. 2021;132:461-472.
doi: 10.1016/j.stem.2023.05.012 doi: 10.1016/j.actbio.2020.12.037

20. Yuan J, Li X, Yu S. Cancer organoid co-culture model system: 32. Cao LQ, Xie Y, Fleishman JS, Liu X, Chen ZS. Hepatocellular
Novel approach to guide precision medicine. Front Immunol. carcinoma and lipid metabolism: Novel targets and
2023;13:1061388. therapeutic strategies. Cancer Lett. 2024;597:217061.
doi: 10.3389/fimmu.2022.1061388 doi: 10.1016/j.canlet.2024.217061
21. Tong L, Cui W, Zhang B, et al. Patient-derived organoids in 33. Broutier L, Mastrogiovanni G, Verstegen MMA, et al. Human
precision cancer medicine. Med. 2024;11:1351-1377. primary liver cancer -derived organoid cultures for disease
modelling and drug screening. Nat Med. 2017;23:1424.
doi: 10.1016/j.medj.2024.08.010
doi: 10.1038/nm.4438
22. Wallaschek N, Niklas C, Pompaiah M, et al. Establishing
pure cancer organoid cultures: Identification, selection and 34. Ji S, Feng L, Fu Z, et al. Pharmaco-proteogenomic
verification of cancer phenotypes and genotypes. J Mol Biol. characterization of liver cancer organoids for precision
2019;431:2884-2893. oncology. Sci Transl Med. 2023;15:eadg3358.
doi: 10.1126/scitranslmed.adg3358
doi: 10.1016/j.jmb.2019.05.031
35. Qiu R, Murata S, Cheng C, et al. A novel orthotopic
23. Veninga V, Voest EE. Tumor organoids: Opportunities
and challenges to guide precision medicine. Cancer Cell. liver cancer model for creating a human-like tumor
2021;39:1190-1201. microenvironment. Cancers (Basel). 2021;13:3997.
doi: 10.1016/j.ccell.2021.07.020 doi: 10.3390/cancers13163997/s1
24. Chalabi M, Fanchi LF, Dijkstra KK, et al. Neoadjuvant 36. Farhangnia P, Khorramdelazad H, Nickho H, Delbandi A.A.
immunotherapy leads to pathological responses in MMR- Current and future immunotherapeutic approaches in
proficient and MMR-deficient early-stage colon cancers. Nat pancreatic cancer treatment. J Hematol Oncol. 2024;17:40.
Med. 2020;26(4):566-576. doi: 10.1186/s13045-024-01561-6

Volume 1 Issue 2 (2025) 11 doi: 10.36922/OR025050008